僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Tepoditamab （MCLA-117） is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab （MCLA-117） kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia （AML） research